Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. Amoxicillin is the first-line antibiotic with coverage for Streptococcus pneumoniae for school-aged children, and treatment should not exceed seven days. Patients requiring hospitalization and...

  2. Abstract. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To compare different antibiotics in order to identify effective and safe antibiotic drug therapies for children with hospital‐acquired pneumonia (HAP) (including ventilator‐associated pneumonia (VAP) and HAP without mechanical ventilation).

  3. Pneumonia has a marked seasonal pattern, with a much higher prevalence throughout the winter due to the preponderance of infections such as respiratory syncytial virus (RSV), influenza and pneumococcus. 1 With so many children affected, pneumonia presents a significant risk to child health and a burden on healthcare resources.

  4. 1 Σεπ 2017 · Management of pediatric community-acquired pneumonia should focus on judicious use of antimicrobial medications, bacterial diagnostics, and surgical drainage when complicated by large effusion and empyema. Treatment in adherence to national guidelines produces favorable outcomes. After completing this article, readers should be able to:

  5. 25 Μαΐ 2023 · Current World Health Organization evidence summaries recommend, in LMICs, 3 to 5 days of antibiotic treatment of children with CAP. 10 Guidelines from the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America recommend 7 to 10 days of antibiotic treatment of outpatient CAP but acknowledge that shorter courses of ...

  6. The World Health Organization recommends a 3-day course of oral amoxicillin for treatment of fast-breathing pneumonia in immunocompetent children and a 5-day course for chest-indrawing pneumonia in children. 5 In contrast, most national guidelines in both high- and low-income countries recommend antibiotics for 5 to 10 days (eTable 1 in the ...

  7. 11 Δεκ 2019 · This document provides guidance in antibiotic and antiviral selection for children with community-acquired pneumonia (CAP). It is not intended to replace clinician judgment in individual cases. However, it should apply to the vast majority of patients diagnosed with CAP.